XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label ...

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ ...

Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, ...

Natera, Inc. , a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking ...

The latest update is out from Antengene Corporation Limited ( ($HK:6996) ). Antengene Corporation Limited announced that the Hong Kong Department ...

Shares of ADC Therapeutics fell after it reported the death of two patients in a late-stage trial for treating an aggressive cancer that starts in white blood cells. The stock fell 7.6% to $4.25 in ...

Investing.com -- ADC Therapeutics SA (NYSE:ADCT) stock fell 22% Wednesday after the company released updated data from its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with the ...

ADC Therapeutics (ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of Zynlonta ...

Results of eleven research studies conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) were selected for presentation at the American Society of Hematology ...

Summary • ADC Therapeutics SA’s stock fell 9% to $4.20 in pre-market trading, driven by broader market sentiment rather than ...

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY(TM) ...